However, cell culture treatment with small molecule Wnt inhibitors that target PORCN or TNK rescued the increased proliferation of INPP4B-overexpressing ER+ breast cancer cells [24], which raises the possibility that ER+ breast cancers with high INPP4B expression may respond to therapies that target the Wnt/β-catenin pathway. This evidence concerns the gene ESR1 and breast carcinoma.